Showing results (171-180 of 192) with videos related to

Sort By:
Pageof 20
JAMA|June 19, 2014
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trialRichard D Carvajal, Jeffrey A Sosman, Jorge Fernando Quevedo, et al.
The New England Journal of Medicine|October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal MelanomaJessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
European Urology|April 9, 2026
Prognostic Value of Interim PSMA-PET Total Tumor Volume for Overall Survival Within ENZA-p, A Randomized Phase 2 Trial of Enzalutamide Versus Enzalutamide Plus [<sup>177</sup>Lu] Lu-PSMA-617 (ANZUP1901)Louise Emmett, Nathan Papa, Oliver Sartor, et al.
The Lancet. Oncology|March 29, 2023
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trialChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
The New England Journal of Medicine|June 4, 2019
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerIan D Davis, Andrew J Martin, Martin R Stockler, et al.
European Urology|May 25, 2021
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation TherapyChristopher J Sweeney, Andrew J Martin, Martin R Stockler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 30, 2025
Metformin Active Surveillance Trial in Low-Risk Prostate CancerNeil E Fleshner, Rui M Bernardino, Jonathan Izawa, et al.
The Lancet. Oncology|December 3, 2023
Overall survival with [<sup>177</sup>Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trialMichael S Hofman, Louise Emmett, Shahneen Sandhu, et al.
JAMA Oncology|March 5, 2026
Genomic Therapy Matching in Rare and Refractory CancersFrank P Lin, Subotheni Thavaneswaran, John P Grady, et al.
Genome Medicine|October 27, 2016
Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trialTracy L Stockley, Amit M Oza, Hal K Berman, et al.
Pageof 20